SG Americas Securities LLC Has $148,000 Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)

SG Americas Securities LLC cut its position in Structure Therapeutics Inc. (NASDAQ:GPCR) by 34.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,445 shares of the company’s stock after selling 2,911 shares during the quarter. SG Americas Securities LLC’s holdings in Structure Therapeutics were worth $148,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in GPCR. JPMorgan Chase & Co. lifted its holdings in shares of Structure Therapeutics by 302.3% in the third quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company’s stock worth $1,489,000 after acquiring an additional 25,500 shares during the last quarter. Vestal Point Capital LP lifted its stake in Structure Therapeutics by 105.4% in the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $50,474,000 after purchasing an additional 590,000 shares during the last quarter. abrdn plc boosted its position in Structure Therapeutics by 132.7% in the third quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after buying an additional 123,789 shares in the last quarter. Barclays PLC grew its stake in shares of Structure Therapeutics by 64.5% during the third quarter. Barclays PLC now owns 81,138 shares of the company’s stock worth $3,562,000 after buying an additional 31,815 shares during the last quarter. Finally, Pier Capital LLC increased its holdings in shares of Structure Therapeutics by 32.7% during the third quarter. Pier Capital LLC now owns 134,291 shares of the company’s stock worth $5,894,000 after buying an additional 33,087 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $24.29 on Tuesday. Structure Therapeutics Inc. has a fifty-two week low of $23.50 and a fifty-two week high of $62.74. The company has a 50 day simple moving average of $29.21 and a two-hundred day simple moving average of $34.91. The company has a market capitalization of $1.39 billion, a PE ratio of -32.82 and a beta of -2.75.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Stifel Nicolaus assumed coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective on the stock. JMP Securities reissued a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.